Dec. 4, 2024 – People taking the weight loss drug Zepbound experienced dramatically greater weight loss than competitor Wegovy in the first head-to-head trial. Those who took Zepbound lost on ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...

Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo Nordisk, in a head-to-head randomized controlled trial. The result ...